Review
Purine analogs in the treatment of chronic lymphocytic leukemia
Affiliations
- PMID: 9178834
Item in Clipboard
Review
Purine analogs in the treatment of chronic lymphocytic leukemia
Leukemia.
1997 Apr.
Abstract
The purine analogs fludarabine (FAMP) and 2-chlorodeoxyadenosine (2-CDA) are highly active in chronic lymphocytic leukemia (CLL). In second-line therapy response rates are in the range of 30 to 60% and exceed 70% when applied to previously untreated patients. While FAMP in particular is thus well established for salvage treatment and can be considered as the present treatment of choice, more data are needed to define the role of purine analogs for first-line therapy.
Similar articles
-
In vitro sensitivity of chronic lymphocytic leukemia B-cells to fludarabine, 2-chlorodeoxyadenosine and chlorambucil: correlation with clinico-hematological and immunophenotypic features.Haematologica. 1996 May-Jun;81(3):224-31. Haematologica. 1996. PMID: 8767527 Clinical Trial.
-
Present status of purine analogs in the therapy of chronic lymphocytic leukemias.Leukemia. 1997 Apr;11 Suppl 2:S29-34. Leukemia. 1997. PMID: 9178835 Review.
-
Rituximab plus fludarabine and cyclophosphamide or other agents in chronic lymphocytic leukemia.Expert Rev Anticancer Ther. 2010 Oct;10(10):1529-43. doi: 10.1586/era.10.132. Expert Rev Anticancer Ther. 2010. PMID: 20942624 Review.
-
Purine nucleoside analogues and combination therapies in B-cell chronic lymphocytic leukemia: dawn of a new era.Leuk Res. 2004 May;28(5):429-42. doi: 10.1016/j.leukres.2003.08.017. Leuk Res. 2004. PMID: 15068894 Review.
-
Pentostatin (Nipent) and chlorambucil with granulocyte-macrophage colony-stimulating factor support for patients with previously untreated, treated, and fludarabine-refractory B-cell chronic lymphocytic leukemia.Semin Oncol. 2000 Apr;27(2 Suppl 5):44-51. Semin Oncol. 2000. PMID: 10877052 Review.